1 active not recruiting, 1 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Caves: new trials by email Literature Review of Caves trials Research Report on Caves
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer EP0057, olaparib, CT scan - Urothelial Carcinoma, Urothelial Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 45 | 2016-05-09 | 2026-08-13 |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Cladribine, Rituximab, BMbx - Hairy Cell Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 175 | 2008-10-20 | 2026-08-18 |
| Treatment and Natural History Study of Lymphomatoid Granulomatosis Interferon, Rituxan and EPOCH, Tumor biopsy - Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid | Phase 2 | Completed | National Cancer Institute (NCI) | 94 | 1995-05-05 | 2025-06-19 |
Carcinoma, Transitional Cell (1) · Epstein-Barr Virus Infections (1) · Leukemia (1) · Leukemia, Hairy Cell (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphomatoid Granulomatosis (1) · Lymphoproliferative Disorders (1) · Neoplasm, Residual (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
National Cancer Institute (NCI) (3)
United States (3)
Anish Thomas, M.D. (1) · Christopher J Melani, M.D. (1) · Robert J Kreitman, M.D. (1)
PMID 32109194, PMID 32897402, PMID 34607348, PMID 37011643, PMID 42820295